Loading...

Novartis AG

NVSNYSE
Healthcare
Drug Manufacturers - General
$115.78
$-0.18(-0.16%)

Novartis AG (NVS) Company Profile & Overview

Explore Novartis AG’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

Novartis AG (NVS) Company Profile & Overview

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

SectorHealthcare
IndustryDrug Manufacturers - General
CEODr. Vasant Narasimhan M.D.

Contact Information

41 61 324 1111
Lichtstrasse 35, Basel, 4056

Company Facts

75,883 Employees
IPO DateNov 7, 1996
CountryCH
Actively Trading

Frequently Asked Questions

;